The Use of Dupilumab in Severe Atopic Dermatitis During Pregnancy: A Case Report

2021 ◽  
Author(s):  
Nabeel H Akhtar ◽  
Touraj Khosravi-Hafshejani ◽  
Daud Akhtar ◽  
Gurbir Dhadwal ◽  
Amin Kanani
Keyword(s):  
Atopic Dermatitis ◽  
Case Report ◽  
Economic Burden ◽  
Safety Profile ◽  
Severe Atopic Dermatitis ◽  
Limited Data ◽  
Systemic Glucocorticoids ◽  
Significant Health ◽  
In Pregnancy

Abstract Atopic dermatitis accounts for most cases of gestational dermatoses. The rising prevalence of atopic dermatitis poses a significant health and economic burden. Current treatments include topical and systemic glucocorticoids and cyclosporine. Presently, the only biologic approved for atopic dermatitis is dupilumab with limited data available regarding its safety profile in pregnancy. We report a case of severe atopic dermatitis treated safely with dupilumab with no adverse maternal or fetal outcomes and resolution of atopic dermatitis postpartum in the absence of maintenance dupilumab therapy. Further research is needed to elucidate the role of dupilumab in the management of atopic dermatitis during pregnancy.

71 Role of food hypersensitivity in mild to severe atopic dermatitis

1988 ◽  
Vol 81 (1) ◽  
pp. 186
Author(s):  
A.W. Burks ◽  
M.A. Sherrill ◽  
S.B. Mallory ◽  
L.W. Williams
Keyword(s):  
Atopic Dermatitis ◽  
Food Hypersensitivity ◽  
Severe Atopic Dermatitis

scholarly journals Frictional melanosis of the areola associated with severe atopic dermatitis: A case report with striking dermoscopic features

TURKDERM ◽  
2018 ◽  
Vol 52 (2) ◽  
pp. 74-75
Author(s):  
Sema Aytekin ◽  
Şirin Yaşar ◽  
Fatih Göktay ◽  
Filiz Cebeci ◽  
Pembegül Güneş
Keyword(s):  
Atopic Dermatitis ◽  
Case Report ◽  
Severe Atopic Dermatitis

scholarly journals Economic Burden of Adult Patients with Moderate to Severe Atopic Dermatitis Indicated for Systemic Treatment

2019 ◽  
Vol 99 (9) ◽  
pp. 762-768 ◽  
Author(s):  
L Ariëns ◽  
K Nimwegen ◽  
M Shams ◽  
D Bruin ◽  
J Schaft ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Economic Burden ◽  
Systemic Treatment ◽  
Adult Patients ◽  
Severe Atopic Dermatitis

scholarly journals Chronic lymphocytic leukaemia in pregnancy: a case report and literature review

2009 ◽  
Vol 2 (4) ◽  
pp. 168-169 ◽  
Author(s):  
Cynthia Maxwell ◽  
Rosheen Grady ◽  
Michael Crump
Keyword(s):  
Case Report ◽  
Literature Review ◽  
Chronic Lymphocytic Leukaemia ◽  
Lymphocytic Leukaemia ◽  
Rare Condition ◽  
Multidisciplinary Care ◽  
Pregnancy Care ◽  
Active Disease ◽  
In Pregnancy

Chronic lymphocytic leukaemia is a rare condition reported in pregnancy. We review a case of a woman presenting for pregnancy care with active disease and review the literature on this condition. This case raises several important issues with regard to managing complex medical diseases such as leukaemia in pregnant women, including the role of multidisciplinary care.

scholarly journals Suicide due to fear of COVID-19, in pregnancy, lead to Neonatal malformations: A case report

2021 ◽  
Author(s):  
Javad Boskabadi ◽  
Saeed Kargar-Soleiman abad ◽  
shahrokh mehrpishe ◽  
Elham Pishavar ◽  
Roya Farhadi
Keyword(s):  
Mental Health ◽  
Case Report ◽  
Antipsychotic Drugs ◽  
First Trimester ◽  
Limited Data ◽  
First Trimester Of Pregnancy ◽  
In Pregnancy

There is limited data about various effect of COVID-19 in pregnancy. The Covid-19 pandemic can increase anxiety or schizophrenia exacerbation. Neonatal malformations from antipsychotic drugs exposures during first trimester of pregnancy have been reported. However, their effect near delivery have been less studied. Keywords: Covid-19, pregnancy, mental health, neonatal malformations

scholarly journals Influence of dupilumab on the economic burden of severe asthma and atopic dermatitis

2020 ◽  
pp. 15-26
Author(s):  
I. S. Krysanov ◽  
V. S. Krysanova ◽  
O. I. Karpov ◽  
V. Yu. Ermakova
Keyword(s):  
Atopic Dermatitis ◽  
Severe Asthma ◽  
Economic Burden ◽  
Weighted Average ◽  
Indirect Costs ◽  
Current Treatment ◽  
Severe Atopic Dermatitis ◽  
Local Conditions ◽  
Economic Burden Of Disease

The prevalence of comorbidity — asthma and atopic dermatitis — is not understood well yet. More severe processes decreasing quality of life and increasing a social-economic burden of disease are occurred in such kind comorbidity.Aim: an evaluation of economic burden of non-control severe asthma in combination with severe atopic dermatitis in the local conditions.Materials and methods. Analysis has been performed for adult patients; the bottom-up approach of costs evaluation was used. Direct medical and non-medical as well as indirect costs were calculated for two models: Model 1 — current practice of the treatment, Model 2 — treatment with Dupilumab. Results. Model 1 — Weighted average expenditures for one patient were 3,1 mln RUR, indirect costs were dominated (76 % from the total), severe atopic dermatitis had 15 % of total. Model 2 (with Dupilumab) — Dupilumab has decreased the total weighted average cost on 903 905 RUR. The total economic burden of comorbidity was 17,6 bln RUR in the current treatment option, and 12,4 bln RUR in Dupilumab hand (different is 5,2 bln RUR, or burden decrease is expected on 29,2 %).Conclusion. The wider introduction of Dupilumab into clinical practice, which allows achieving control in the treatment of severe asthma and severe atopic dermatitis, should reduce treatment costs and reduce the socio-economic burden of these diseases as a result.

scholarly journals Systematic Review on the Efficacy and Safety of Oral Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis

2021 ◽  
Vol 8 ◽  
Author(s):  
Michelle Le ◽  
Melissa Berman-Rosa ◽  
Feras M. Ghazawi ◽  
Marc Bourcier ◽  
Loretta Fiorillo ◽  
...  
Keyword(s):  
Systematic Review ◽  
Atopic Dermatitis ◽  
Safety Profile ◽  
Kinase Inhibitors ◽  
Meta Analysis ◽  
Symptom Control ◽  
Janus Kinase ◽  
Severe Atopic Dermatitis ◽  
Eligibility Criteria ◽  
Janus Kinase Inhibitors

Background: Atopic dermatitis is a chronic, relapsing and remitting disease that can be difficult to treat despite a recently approved biologic therapy targeting IL-4/IL-13 receptor. Oral janus kinase inhibitors (JAKi) represent a novel therapeutic class of targeted therapy to treat moderate-to-severe atopic dermatitis (AD).Objective: To review the efficacy, safety, and pharmacokinetic characteristics of oral JAKi in the treatment of AD.Methods: A PRISMA systematic review was conducted using MEDLINE, EMBASE (Ovid), and PubMed databases for studies assessing the efficacy, safety, and/or pharmacokinetic properties of oral forms of JAKi in the treatment of AD in pediatric or adult populations from inception to June 2021.Results: 496 papers were reviewed. Of 28 articles that underwent full text screening, 11 met our inclusion criteria for final qualitative review. Four studies examined abrocitinib; three studies examined baricitinib; three examined upadacitinib and one examined gusacitinib (ASN002). Significant clinical efficacy and a reassuring safety profile was reported for all JAKi agents reviewed. Rapid symptom control was reported for abrocitinib, baricitinib and upadacitinib.Limitations: Given the relatively limited evidence for each JAKi and the differences in patient eligibility criteria between studies, the data was not deemed suitable for a meta-analysis at this time.Conclusion: Given their ability to achieve rapid symptom control with a reassuring safety profile, we recommend considering the use of JAKi as a reliable systemic treatment option for adult patients with moderate-to-severe AD, who are unresponsive to topical or skin directed treatments.

scholarly journals Participation of Neuropeptides and β-endorphin in Pathogenesis of Atopic Dermatitis. Evaluation of Levocetirizine Effectiveness upon Neuropeptides' Levels at Children with Atopic Dermatitis

2009 ◽  
Vol 7 (2) ◽  
pp. 74-80
Author(s):  
V A Revyakina ◽  
A S Agaphonov ◽  
T B Sentsova ◽  
M P Phabrika
Keyword(s):  
Atopic Dermatitis ◽  
Clinical Symptoms ◽  
Signs And Symptoms ◽  
Severe Atopic Dermatitis ◽  
Neurokinin A ◽  
Double Blind ◽  
Developmental Mechanisms ◽  
Days Of Therapy

Objective. Determination of the role of neuropeptides and p-endorphin in developmental mechanisms of atopic dermatitis, and assessment of the effectiveness of levocetirizine, a modern Hl-antihistamine, on atopic dermatitis symptoms and its influence on the SCORAD index in children with atopic dermatitis. Materials and methods. 84 children with atopic dermatitis of moderate-to-severe or severe clinical nature, aged 1 to 17 years, were enrolled in this (double-blind or open, randomised, etc.) study. Patients were treated with levocetirizine 5 mg once daily during 14 days. The levels of P substance, neurokinin A, neurokinin B, and p-endorphin in blood serum, as well as levocetirizine effectiveness on disease symptoms and the SCORAD index were evaluated. Results. Lower neuropeptide levels were associated with disease severity; children with severe atopic dermatitis had lower neuropeptide values. Before treatment, SCORAD index in children with severe atopic dermatitis was 76,5±11,3, and after 7 days of therapy SCORAD index was 14±6,2 points (p< 0,01). By the 7th day after treatment initiation, the acute atopic dermatitis became of subacute nature and was accompanied by a regression of the cutaneous eruption in the form of significant decreasing of skin manifestations and pruritus, absence of new eruption and normalized sleep. In children with moderate-to-severe atopic dermatitis the SCORAD index before levocetirizine treatment was 44,2±3,4 points; on the 3rd day, this index was 20,4±2,6 points; and on the 7th day there was a complete absence of clinical symptoms of the main disease. Levocetirizine administration led to the disappearance of the disease clinical symptoms and pruritus in children with moderate-to-severe atopic dermatitis. Conclusion. This trial demonstrated that neuropeptides are involved in the developmental mechanisms of atopic dermatitis and that levocetirizine can significantly improve the signs and symptoms of children with moderate-to-severe or severe atopic dermatitis.

scholarly journals PSY12 Economic Burden of Severe Atopic Dermatitis in Russia

2020 ◽  
Vol 23 ◽  
pp. S744
Author(s):  
V. Krysanova ◽  
I. Krysanov ◽  
V. Ermakova
Keyword(s):  
Atopic Dermatitis ◽  
Economic Burden ◽  
Severe Atopic Dermatitis
Sign in / Sign up

Export Citation Format

Share Document